Clinical Trial Update: Vigabatrin and Insulin Sensitivity [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating vigabatrin for insulin sensitivity in non-alcoholic fatty liver disease and obesity has completed and results were posted on 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Obesity

Drugs mentioned

• Vigabatrin (Vigabatrin)

Snippet

Sponsor: Washington University School of Medicine | Conditions: NAFLD, Obesity | Phase 2 | Status: COMPLETED | Results posted: 2025-01-14